Playback speed
10 seconds
Progression on First-Line Therapy in HR+, HER2- MBC: Treatments and Sequencing
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
By
Lilly Medical Affairs
FEATURING
Joyce O’Shaughnessy
961 views
July 24, 2024
In this video, Dr. Joyce O’Shaughnessy discusses the treatment landscape for patients who progress on ET + CDK4/6 inhibitors, including the importance of biomarker testing in this setting.
To access additional videos and download free resources, click here.
VV-OTHR-US-DEL-3129 © 2024 Lilly USA, LLC. All Rights Reserved.
Comments are disabled for this content.